TheraRadar
← Back
Data updated: Jul 17, 2026

Baxalta US Inc.

Biotech
Pharmaceuticals

Baxalta US Inc. is a biotechnology company with 1 FDA-approved products.

1970
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics

Baxalta US Inc.'s Key Drugs

Baxalta US Inc.'s key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

Baxalta US Inc.'s Recent FDA Approvals

New NDA/BLA approvals for Baxalta US Inc. over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

Baxalta US Inc.'s Therapeutic Areas

Disease areas where Baxalta US Inc. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

Baxalta US Inc. Pipeline Snapshot

Active clinical trials for Baxalta US Inc. across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling